Pfizer Inc. said Monday it has agreed to buy biotech Medivation Inc. for $81.50 a share, valuing the total company at about $14 billion, in a move that adds one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer’s portfolio
http://www.marketwatch.com/story/pf...behemoth-medivation-for-14-billion-2016-08-22
Pfizer Inc. said Monday it has agreed to buy biotech Medivation...
Add to My Watchlist
What is My Watchlist?